Yumanity Therapeutics has raised a $45m Series A venture capital round, which will fund continued drug discovery related to neurodegenerative diseases caused by protein misfolding, but the company's first clinical trials probably will be financed through additional financing or potential partnership agreements.
Chairman and CEO Tony Coles, who as CEO of Onyx Pharmaceuticals sold that company to Amgen Inc. for more than $10bn in 2013, co-funded and launched Yumanity in late 2014 with scientific co-founder Susan Lindquist
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
